Tirzepatide reduces albuminuria in patients with type 2 diabetes: post-hoc pooled analysis of SURPASS 1-5

被引：0
|
作者：
Wiese, R. J. [1 ]
Heerspink, H. J. L. [2 ]
Tuttle, K. R. [3 ]
Pavo, I. [1 ]
Haupt, A. [1 ]
Yang, Z. [1 ]
Hemmingway, A. [1 ]
Cherney, D. Z. I. [4 ]
Sattar, N. [5 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[3] Univ Washington, Providence Hlth Care, Spokane, WA USA
[4] Univ Toronto, Univ Hlth Network, Toronto Gen Hosp, Div Nephrol,Dept Med, Toronto, ON, Canada
[5] Univ Glasgow, Glasgow, Lanark, Scotland
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [21] Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program
    Frias, Juan Pablo
    Galindo, Rodolfo J.
    Wang, Hui
    Malik, Raleigh E.
    Chivukula, K. Karthik
    Maldonado, Juan M.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (02): : 557 - 568
  • [22] Tirzepatide vs basal insulins in people with type 2 diabetes and different baseline glycaemic patterns: post-hoc analyses of the SURPASS-3 and-4 trials
    Giorgino, F.
    Franco, D. R.
    Nicolay, C.
    Hemmingway, A.
    Rodriguez, A.
    Wiese, R. J.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S315 - S315
  • [23] Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials
    Warren, Mark
    Chaykin, Louis
    Trachtenbarg, David
    Nayak, Gurudutt
    Wijayasinghe, Nelun
    Cariou, Bertrand
    DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2291 - 2297
  • [24] Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
    Heerspink, Hiddo J. L.
    Sattar, Naveed
    Pavo, Imre
    Haupt, Axel
    Duffin, Kevin L.
    Yang, Zhengyu
    Wiese, Russell J.
    Tuttle, Katherine R.
    Cherney, David Z. I.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (11): : 774 - 785
  • [25] Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis
    Glass, Leonard C.
    Qu, Yongming
    Lenox, Sheila
    Kim, Dennis
    Gates, Jeffrey R.
    Brodows, Robert
    Trautmann, Michael
    Bergenstal, Richard M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (03) : 639 - 644
  • [26] Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial
    Hankosky, Emily R.
    Wang, Hui
    Neff, Lisa M.
    Kan, Hong
    Wang, Fangyu
    Ahmad, Nadia N.
    Stefanski, Adam
    Garvey, W. Timothy
    DIABETES OBESITY & METABOLISM, 2023, 25 (12): : 3748 - 3756
  • [27] Lixisenatide and renal outcomes in patients with type 2 diabetes: a post-hoc analysis of the ELIXA trial
    Muskiet, M. H. A.
    Heerspink, H. J. L.
    Tonneijck, L.
    Huang, Y.
    Liu, M.
    Saremi, A.
    van Raalte, D. H.
    DIABETOLOGIA, 2018, 61 : S40 - S40
  • [28] Baseline HOMA2-B can predict tirzepatide efficacy: post hoc analysis of the SURPASS-1 and SURPASS-2 studies
    Peleshok, J.
    Hsia, S. H.
    Mathieu, C.
    Thomas, M. K.
    Wang, H.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S314 - S315
  • [29] Effect of tirzepatide on kidney parameters in people with excess body weight and type 2 diabetes: a post-hoc analysis of the SURMOUNT-2 trial
    Heerspink, H. J. L.
    Friedman, A. N.
    Bjornstad, P.
    van Raalte, D. H.
    Cao, D.
    Garcia-Perez, L. -E.
    Stefanski, A.
    Turfanda, I.
    Bunck, M. C.
    Benabbad, I.
    de Oliveira, C. Piras
    Griffin, R.
    DIABETOLOGIA, 2024, 67 : S355 - S356
  • [30] Baseline HOMA2-B Can Predict Tirzepatide Efficacy-Post Hoc Analysis of the SURPASS-1 and SURPASS-2 Studies
    Hsia, Stanley H.
    Thomas, Melissa K.
    Mathieu, Chantal
    Wang, Hui
    Peleshok, Jennifer
    DIABETES, 2023, 72
12345